Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition

Trends in Cardiovascular Medicine

Volumn 24, Issue 4, 2014, Pages 142-148

  Violi, Francesco ^a   Carnevale, Roberto ^a   Pastori, Daniele ^a   Pignatelli, Pasquale ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CYBB PROTEIN, HUMAN; ENZYME INHIBITOR; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; PYRROLE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HUMAN; OXIDATIVE STRESS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ANTIOXIDANTS; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; OXIDATIVE STRESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRROLES; REACTIVE OXYGEN SPECIES; THROMBOSIS;

EID: 84899478818     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2013.09.006     Document Type: Review

References (64)

1. Alber H.F., Frick M., Suessenbacher A., et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease-A randomized, placebo-controlled study. American Heart Journal 2006, 151:139.
2. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002, 324:71-86.
3. Basili S., Pignatelli P., Tanzilli G., et al. Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:1766-1771.
4. Bea F., Blessing E., Shelley M.I., Shultz J.M., Rosenfeld M.E. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003, 167:187-194.
5. Blann A.D., Gurney D., Hughes E., Buggins P., Silverman S.H., Lip G.Y. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. The American Journal of Cardiology 2001, 88(A7-8):89-92.
6. Brass L.F., Zhu L., Stalker T.J. Minding the gaps to promote thrombus growth and stability. The Journal of Clinical Investigation 2005, 115:3385-3392.
7. Cangemi R., Pignatelli P., Carnevale R., et al. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 2012, 61:1626-1632.
8. Carnevale R., Iuliano L., Nocella C., et al. Relationship between platelet and urinary 8-Iso-PGF2alpha levels in subjects with different degrees of NOX2 regulation. Journal of the American Heart Association 2013, 2:e000198.
9. Carnevale R., Loffredo L., Pignatelli P., et al. Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. Journal of Thrombosis And Haemostasis 2012, 10:125-132.
10. Carter N.J. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions 2010, 10:383-400.
11. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24:1980-1987.
12. Chou T.C., Lin Y.F., Wu W.C., Chu K.M. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin. British Journal of Pharmacology 2008, 153:1281-1287.
13. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. American Heart Journal 2004, 147:293-300.
14. Davi G., Patrono C. Platelet activation and atherothrombosis. The New England Journal of Medicine 2007, 357:2482-2494.
15. Dayal S., Wilson K.M., Motto D.G., Miller F.J., Chauhan A.K., Lentz S.R. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation 2013, 127:1308-1316.
16. Del Principe D., Menichelli A., De Matteis W., et al. Hydrogen peroxide is an intermediate in the platelet activation cascade triggered by collagen, but not by thrombin. Thrombosis Research 1991, 62:365-375.
17. Du X., Gu M., Weisel J.W., et al. Long range propagation of conformational changes in integrin alpha IIb beta 3. The Journal of Biological Chemistry 1993, 268:23087-23092.
18. Dubois C., Panicot-Dubois L., Gainor J.F., Furie B.C., Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. The Journal of Clinical Investigation 2007, 117:953-960.
19. Dubois C., Panicot-Dubois L., Merrill-Skoloff G., Furie B., Furie B.C. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006, 107:3902-3906.
20. Evangelista V., Manarini S., Dell'Elba G., et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thrombosis and Haemostasis 2005, 94:568-577.
21. Gertz K., Laufs U., Lindauer U., et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003, 34:551-557.
22. Gresele P., Cerletti C., Guglielmini G., Pignatelli P., de Gaetano G., Violi F. Effects of resveratrol and other wine polyphenols on vascular function: an update. The Journal of Nutritional Biochemistry 2011, 22:201-211.
23. Ignarro L.J. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. Journal of Physiology and Pharmacology 2002, 53:503-514.
24. Istvan E.S. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. American Heart Journal 2002, 144:S27-S32.
25. Jin R.C., Mahoney C.E., Coleman Anderson L., et al. Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo. Circulation 2011, 123:1963-1973.
26. Khemasuwan D., Chae Y.K., Gupta S., et al. Dose-related effect of statins in venous thrombosis risk reduction. The American Journal of Medicine 2011, 124:852-859.
27. Krotz F., Sohn H.Y., Gloe T., et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002, 100:917-924.
28. Leo R., Pratico D., Iuliano L., et al. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation 1997, 95:885-891.
29. Liu Y., Davidson B.P., Yue Q., et al. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circulation. Cardiovascular Imaging 2013, 6:74-82.
30. Loscalzo J. The identification of nitric oxide as endothelium-derived relaxing factor. Circulation Research 2013, 113:100-103.
31. Ludman A., Venugopal V., Yellon D.M., Hausenloy D.J. Statins and cardioprotection-more than just lipid lowering?. Pharmacology & Therapeutics 2009, 122:30-43.
32. Mangin P., Yap C.L., Nonne C., et al. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood 2006, 107:4346-4353.
33. Marcus A.J., Broekman M.J., Pinsky D.J. COX inhibitors and thromboregulation. The New England Journal of Medicine 2002, 347:1025-1026.
34. Marcus A.J., Silk S.T., Safier L.B., Ullman H.L. Superoxide production and reducing activity in human platelets. The Journal of Clinical Investigation 1977, 59:149-158.
35. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731.
36. Moscardo A., Valles J., Latorre A., Madrid I., Santos M.T. Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Thrombosis Research 2013, 131:e154-e159.
37. Notarbartolo A., Davi G., Averna M., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 1995, 15:247-251.
38. Patti G., Cannon C.P., Murphy S.A., et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011, 123:1622-1632.
39. Phillips D.R., Fitzgerald L.A., Charo I.F., Parise L.V. The platelet membrane glycoprotein IIb/IIIa complex. Structure, function, and relationship to adhesive protein receptors in nucleated cells. Annals of the New York Academy of Sciences 1987, 509:177-187.
40. Pignatelli P., Carnevale R., Cangemi R., et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:360-367.
41. Pignatelli P., Carnevale R., Di Santo S., et al. Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. Biochemical Pharmacology 2012, 84:1635-1642.
42. Pignatelli P., Carnevale R., Di Santo S., et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:423-434.
43. Pignatelli P., Carnevale R., Pastori D., et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 2012, 126:92-103.
44. Pignatelli P., Di Santo S., Barilla F., Gaudio C., Violi F. Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. Journal of Thrombosis and Haemostasis 2008, 6:1832-1834.
45. Pignatelli P., Pulcinelli F.M., Lenti L., Gazzaniga P.P., Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998, 91:484-490.
46. Pignatelli P., Sanguigni V., Lenti L., et al. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004, 110:1326-1329.
47. Pignatelli P., Sanguigni V., Lenti L., et al. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. Journal of Thrombosis and Haemostasis 2007, 5:1170-1178.
48. Pratico D., Smyth E.M., Violi F., FitzGerald G.A. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. The Journal of Biological Chemistry 1996, 271:14916-14924.
49. Puccetti L., Pasqui A.L., Pastorelli M., et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. European Journal of Clinical Investigation 2002, 32:901-908.
50. Pucci A., Sheiban I., Formato L., et al. In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. Atherosclerosis 2007, 194:189-195.
51. Seno T., Inoue N., Gao D., et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thrombosis Research 2001, 103:399-409.
52. Serebruany V.L., Miller M., Pokov A.N., et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). The American Journal of Cardiology 2006, 97:1332-1336.
53. Sommeijer D.W., Joop K., Leyte A., Reitsma P.H., ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. Journal of Thrombosis and Haemostasis 2005, 3:1168-1171.
54. Sugamura K., Keaney J.F. Reactive oxygen species in cardiovascular disease. Free Radical Biology & Medicine 2011, 51:978-992.
55. Tannous M., Cheung R., Vignini A., Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thrombosis and Haemostasis 1999, 82:1390-1394.
56. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology 1971, 231:232-235.
57. Violi F., Pignatelli P. Aspirin resistance: is this term meaningful?. Current Opinion in Hematology 2006, 13:331-336.
58. Violi F., Pignatelli P. Platelet oxidative stress and thrombosis. Thrombosis Research 2012, 129:378-381.
59. Violi F., Sanguigni V., Loffredo L., et al. Nox2 is determinant for ischemia-induced oxidative stress and arterial vasodilatation: a pilot study in patients with hereditary Nox2 deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26:e131-e132.
60. Walford G., Loscalzo J. Nitric oxide in vascular biology. Journal of Thrombosis and Haemostasis 2003, 1:2112-2118.
61. Williams H.C., Griendling K.K. NADPH oxidase inhibitors: new antihypertensive agents?. Journal of Cardiovascular Pharmacology 2007, 50:9-16.
62. Winchester D.E., Wen X., Xie L., Bavry A.A. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. Journal of the American College of Cardiology 2010, 56:1099-1109.
63. Yokoyama S., Ikeda H., Haramaki N., Yasukawa H., Katoh A., Imaizumi T. HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats. Journal of Cardiovascular Pharmacology 2005, 45:375-381.
64. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine 2001, 345:494-502.